EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

RESPONSE TO RITUXIMAB IN NON-HODGKIN LYMPHOMA PATIENTS AT NATIONAL ONCOLOGY CENTER, ADEN, YEMEN, 2017-2020: RETROSPECTIVE COHORT STUDY

Magdi Saif Aldaeri*, Gamal Abdul Hamid, Mohammed A. Al Amad and Yasser Ghaleb

ABSTRACT

Background: The study aimed to determine the long-term response of rituximab on Non-Hodgkin Lymphomas (NHL) patients. Methods: A retrospective cohort study was conducted in the National Oncology Center in Aden by review of medical registries for NHL patients from 2017-2020. SPSS version 23 was used for the analysis of data, and Kaplan Meier survival curve was used to measure overall survival (OS) and progression-free survival (PFS) between two groups CHOP and R-CHOP in two follow up periods (12-months and 4-years). Cox regression was used to evaluate the association between the risk factors. Results: Of 100 patients, 50 for each group of CHOP and R-CHOP. < 60 years represented 70%. Advanced Stage represented 64% and DLBCL represented 47% of all subtypes of NHL. Significant association difference in OS in two periods of follow-up (12-month and 4-years) for CHOP vs. R-CHOP was 63% vs. 86%, and 10% vs. 33%, respectively (P=0.01 and P=0.04). In contrast, the difference was non-statically significant in the PFS in two periods 39% vs. 66%, and 12% vs. 27% for CHOP vs. R-CHOP, respectively (P=0.10 and P=0.31). The age group > 60 years, ≥ 6 cycles of chemotherapy received, abnormality of LDH, and married patients were the significantly hazard proportion (P< 0.05). Conclusion: The addition of rituximab to CHOP had a statistical difference in OS and there is no difference in PFS. Elderly, married patients, > 6 cycles of chemotherapy received, and abnormality LDH were poor prognostic factors. Providing oncology center with rituximab for ongoing use it of NHL patients are recommended.

Keywords: Non-Hodgkin lymphoma, CHOP, rituximab, Survival, Yemen.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 July 2022 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: JULY ISSUE PUBLISHED

    JULY Issue has been successfully launched on 1 July 2022.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database